Sanofi-Aventis acquires marketing rights to Xyzal
This article was originally published in The Tan Sheet
Sanofi-Aventis assumes the U.S. marketing rights to UCB's prescription allergy drug Xyzal (levocetirizine dihydrochloride), which could be a future switch candidate. Belgium-based UCB licensed the marketing rights to Sanofi as part of an accelerated plan to transition its U.S. business to a purely specialty-focused biopharmaceutical company, UCB announced Jan. 29. The firm says it will exit the primary care market March 1. However, UCB will continue to receive a percentage of Xyzal profits, according to the release. The deal comes weeks after Sanofi acquired U.S.-based Chattem with the intention of using the company to switch its prescription allergy drug Allegra (1"The Tan Sheet" Jan. 4, 2010). The French firm may have plans for Xyzal to follow a similar potential switch path. Xyzal's patent exclusivity expires in 2013 and the drug is the follow-on to cetirizine - the active ingredient in McNeil Consumer Healthcare's OTC allergy drug Zyrtec. Sanofi is expanding its OTC business through acquisitions, mergers and joint ventures, like its partnership with Minsheng Pharmaceutical Group in China (see story p. 6)
You may also be interested in...
Sanofi Eyes Chattem As Key Building Block For Global OTC Growth
Sanofi-Aventis' $1.9 billion bid for OTC and personal care product firm Chattem offers the French firm a coveted toehold in the sizeable U.S. consumer health care market while also opening potential opportunities in emerging markets
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.
For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion
After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.